Trial Profile
Phase I Dose-Escalation Study, to Evaluate the Safety, Tolerability and Pharmacokinetics of a Topical Compound 31543 (Calcitriol, USP) in Adult Cancer Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Advanced or Recurrent Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Calcitriol (Primary)
- Indications Alopecia
- Focus Adverse reactions
- Sponsors Berg Pharma
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 03 Jun 2019 According to an Berg Pharma media release, key results from this study were presented at the 2019 ASCO Annual Meeting.
- 19 Oct 2018 According to a Berg Pharma media release, final data from the study will be presented at the ESMO 2018 Annual Congress.